Table 2. Characteristics and management of women in the eclampsia group before the eclamptic event.
| Eclampsia | ||||||
|---|---|---|---|---|---|---|
| n = 51 | ||||||
| Characteristics before eclampsia | n (%) | |||||
| Maximum blood pressure ≥ 160/110 mmHg | 16/51 (64.7%) | |||||
| If yes (n = 16): | Antihypertensive treatment | 9 (56%) | ||||
| Lack of antihypertensive treatment | 7 (44%) | |||||
| Premonitory symptomsa | 19/49 (38.8%) | |||||
| If yes (n = 19): | Hospitalisation | 16 (84%) | ||||
| Lack of hospitalisation | 3 (16%) | |||||
| Pre-eclampsia diagnosed before eclampsia | 33/51 (65%) | |||||
| If yes (n = 33): | Lack of antihypertensive treatment | 17 (52%) | ||||
| Lack of hospitalisation | 14 (42%) | |||||
| Maximum systolic blood pressure ≥160 mmHg | 14 (42%) | |||||
| Maximum diastolic blood pressure ≥110 mmHg | 6 (18%) | |||||
| Premonitory symptoms | 14 (42%) | |||||
| Magnesium sulphate prophylaxisb | 1 (3%) | |||||
| If no (n = 18): | Maximum | 2 (11%) | ||||
| sSystolic blood pressure ≥160 mmHg | ||||||
| Maximum diastolic blood pressure ≥110 mmHg | 0 | |||||
| Premonitory symptoms | 5 (28%) | |||||
| Magnesium sulphate prophylaxis | 0 | |||||
a:headaches, visual disturbance, epigastric pain, nausea, vomiting, edema, hyper-reflexia, tinnitus, other
b: magnesium sulphate prophylaxis administered 45 minutes before the convulsions